Corporate ActionAug 10, 2026, 05:33 PM
Silexion Therapeutics Plans Public Offering of Shares & Warrants
AI Summary
Silexion Therapeutics Corp. announced a best-efforts public offering of up to 2,673,796 ordinary shares and an equal number of ordinary warrants, along with pre-funded warrants and placement agent warrants. The assumed public offering price is $1.87 per share and ordinary warrant. Concurrently, the company initiated a Phase 2/3 clinical trial for its lead product candidate, SIL204, for locally advanced pancreatic cancer in Israel and Germany. This offering aims to raise capital, following recent efforts to regain Nasdaq compliance and multiple reverse share splits.
Key Highlights
- Silexion Therapeutics announced a best-efforts public offering of up to 2,673,796 ordinary shares.
- The offering includes up to 2,673,796 ordinary warrants and pre-funded warrants.
- Assumed public offering price is $1.87 per share and ordinary warrant.
- H.C. Wainwright & Co. LLC is the exclusive placement agent, receiving a 7.0% cash fee.
- Initiated Phase 2/3 clinical trial for lead product candidate SIL204 in late July 2026.
- Company regained Nasdaq compliance for listing requirements in September 2025.
- Completed a 1-for-10 reverse share split on May 26, 2026.
- Raised approximately $1.0 million gross proceeds from May 2026 warrant exercises.
Price Impact
More from SLXN